Viracta Therapeutics (VIRX) Stock Forecast, Price Target & Predictions
VIRX Stock Forecast
Viracta Therapeutics stock forecast is as follows: an average price target of $8.00 (represents a 3900.00% upside from VIRX’s last price of $0.20) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
VIRX Price Target
VIRX Analyst Ratings
Viracta Therapeutics Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Nov 11, 2022 | - | RBC Capital | $8.00 | $3.33 | 140.24% | 3900.00% |
Viracta Therapeutics Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | - |
Avg Price Target | - | - | - |
Last Closing Price | $0.20 | $0.20 | $0.20 |
Upside/Downside | -100.00% | -100.00% | -100.00% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
May 23, 2024 | Oppenheimer | Outperform | Outperform | Hold |
Nov 11, 2022 | RBC Capital | Outperform | Outperform | Hold |
Viracta Therapeutics Financial Forecast
Viracta Therapeutics Revenue Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 21 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | $120.00K | $2.07M | - | - | - |
Avg Forecast | - | - | - | - | - | - | - | $4.50M | $375.00K | $375.00K | $625.00K | $200.00K | $200.00K | $300.00K |
High Forecast | - | - | - | - | - | - | - | $4.50M | $375.00K | $375.00K | $625.00K | $200.00K | $200.00K | $300.00K |
Low Forecast | - | - | - | - | - | - | - | $4.50M | $375.00K | $375.00K | $625.00K | $200.00K | $200.00K | $300.00K |
# Analysts | - | - | - | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Surprise % | - | - | - | - | - | - | - | - | - | 0.32% | 3.32% | - | - | - |
Viracta Therapeutics EBITDA Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 21 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
EBITDA | - | - | - | - | - | - | - | $-79.11M | $-6.33M | $-5.81M | $-5.29M | $-5.87M | $-6.13M | $-5.60M |
Avg Forecast | - | - | - | - | - | - | - | $900.00K | $75.00K | $75.00K | $125.00K | $40.00K | $40.00K | $60.00K |
High Forecast | - | - | - | - | - | - | - | $900.00K | $75.00K | $75.00K | $125.00K | $40.00K | $40.00K | $60.00K |
Low Forecast | - | - | - | - | - | - | - | $900.00K | $75.00K | $75.00K | $125.00K | $40.00K | $40.00K | $60.00K |
Surprise % | - | - | - | - | - | - | - | -87.90% | -84.33% | -77.49% | -42.34% | -146.73% | -153.20% | -93.28% |
Viracta Therapeutics Net Income Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 21 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Net Income | - | - | - | - | - | - | - | $-79.62M | $-6.39M | $-7.09M | $-5.36M | $-6.01M | $-6.35M | $-6.12M |
Avg Forecast | $-6.70M | $-6.70M | $-8.67M | $-8.28M | $-7.49M | $-10.51M | $-14.45M | $-1.63B | $-75.85M | $-96.54M | $-99.99M | $-117.23M | $-137.92M | $-237.91M |
High Forecast | $-6.70M | $-6.70M | $-8.67M | $-8.28M | $-7.49M | $-10.51M | $-14.45M | $-1.30B | $-75.85M | $-96.54M | $-99.99M | $-117.23M | $-137.92M | $-237.91M |
Low Forecast | $-6.70M | $-6.70M | $-8.67M | $-8.28M | $-7.49M | $-10.51M | $-14.45M | $-1.96B | $-75.85M | $-96.54M | $-99.99M | $-117.23M | $-137.92M | $-237.91M |
Surprise % | - | - | - | - | - | - | - | 0.05% | 0.08% | 0.07% | 0.05% | 0.05% | 0.05% | 0.03% |
Viracta Therapeutics SG&A Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 21 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
SG&A | - | - | - | - | - | - | - | $3.84M | $2.06M | $2.23M | $2.48M | $2.51M | $2.52M | $2.44M |
Avg Forecast | - | - | - | - | - | - | - | $47.13M | $3.93M | $3.93M | $6.55M | $2.09M | $2.09M | $3.14M |
High Forecast | - | - | - | - | - | - | - | $47.13M | $3.93M | $3.93M | $6.55M | $2.09M | $2.09M | $3.14M |
Low Forecast | - | - | - | - | - | - | - | $47.13M | $3.93M | $3.93M | $6.55M | $2.09M | $2.09M | $3.14M |
Surprise % | - | - | - | - | - | - | - | 0.08% | 0.53% | 0.57% | 0.38% | 1.20% | 1.20% | 0.78% |
Viracta Therapeutics EPS Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 21 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
EPS | - | - | - | - | - | - | - | $-5.25 | $-0.17 | $-0.19 | $-0.48 | $-0.57 | $-0.88 | $-1.03 |
Avg Forecast | $-0.17 | $-0.17 | $-0.22 | $-0.21 | $-0.19 | $-0.27 | $-0.37 | $0.02 | $-1.93 | $-2.45 | $-2.54 | $-2.98 | $-3.50 | $-6.04 |
High Forecast | $-0.17 | $-0.17 | $-0.22 | $-0.21 | $-0.19 | $-0.27 | $-0.37 | $0.02 | $-1.93 | $-2.45 | $-2.54 | $-2.98 | $-3.50 | $-6.04 |
Low Forecast | $-0.17 | $-0.17 | $-0.22 | $-0.21 | $-0.19 | $-0.27 | $-0.37 | $0.02 | $-1.93 | $-2.45 | $-2.54 | $-2.98 | $-3.50 | $-6.04 |
Surprise % | - | - | - | - | - | - | - | -225.00% | 0.09% | 0.08% | 0.19% | 0.19% | 0.25% | 0.17% |
Viracta Therapeutics Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
SQZ | SQZ Bio | $0.44 | $400.00 | 90809.09% | Buy |
VIRX | Viracta Therapeutics | $0.20 | $8.00 | 3900.00% | Buy |
ALXO | ALX Oncology | $1.49 | $24.50 | 1544.30% | Buy |
VINC | Vincerx Pharma | $0.36 | $3.00 | 733.33% | Buy |
XFOR | X4 Pharmaceuticals | $0.53 | $3.67 | 592.45% | Buy |
CABA | Cabaletta Bio | $4.00 | $16.33 | 308.25% | Buy |
INZY | Inozyme Pharma | $4.42 | $14.67 | 231.90% | Buy |
TRVI | Trevi Therapeutics | $3.04 | $8.00 | 163.16% | Buy |
BMEA | Biomea Fusion | $8.84 | $22.75 | 157.35% | Buy |
EYPT | EyePoint Pharmaceuticals | $11.70 | $30.00 | 156.41% | Buy |
STOK | Stoke Therapeutics | $13.10 | $30.60 | 133.59% | Buy |
BCYC | Bicycle Therapeutics | $23.46 | $54.40 | 131.88% | Buy |
TERN | Terns Pharmaceuticals | $7.10 | $14.25 | 100.70% | Buy |
LYRA | Lyra Therapeutics | $0.26 | $0.50 | 92.31% | Hold |
MREO | Mereo BioPharma Group | $4.01 | $6.75 | 68.33% | Buy |
LPTX | Leap Therapeutics | $3.67 | $5.50 | 49.86% | Buy |
IGMS | IGM Biosciences | $15.69 | $20.33 | 29.57% | Buy |
VIRX Forecast FAQ
Is Viracta Therapeutics a good buy?
Yes, according to 2 Wall Street analysts, Viracta Therapeutics (VIRX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of VIRX's total ratings.
What is VIRX's price target?
Viracta Therapeutics (VIRX) average price target is $8 with a range of $8 to $8, implying a 3900.00% from its last price of $0.2. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Viracta Therapeutics stock go up soon?
According to Wall Street analysts' prediction for VIRX stock, the company can go up by 3900.00% (from the last price of $0.2 to the average price target of $8), up by 3900.00% based on the highest stock price target, and up by 3900.00% based on the lowest stock price target.
Can Viracta Therapeutics stock reach $0?
VIRX's average twelve months analyst stock price target of $8 supports the claim that Viracta Therapeutics can reach $0 in the near future.
What are Viracta Therapeutics's analysts' financial forecasts?
Viracta Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-32.444M (high $-32.444M, low $-32.444M), average SG&A $0 (high $0, low $0), and average EPS is $-0.823 (high $-0.823, low $-0.823). VIRX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-30.342M (high $-30.342M, low $-30.342M), average SG&A $0 (high $0, low $0), and average EPS is $-0.77 (high $-0.77, low $-0.77).
Did the VIRX's actual financial results beat the analysts' financial forecasts?
Based on Viracta Therapeutics's last annual report (Dec 2019), the company's revenue was $2.07M, beating the average analysts forecast of $1.32M by 56.45%. Apple's EBITDA was $-22.886M, missing the average prediction of $265K by -8736.36%. The company's net income was $-23.844M, missing the average estimation of $-593M by -95.98%. Apple's SG&A was $9.95M, missing the average forecast of $13.88M by -28.31%. Lastly, the company's EPS was $-2.74, missing the average prediction of $-15.05 by -81.79%. In terms of the last quarterly report (Mar 2020), Viracta Therapeutics's revenue was $120K, missing the average analysts' forecast of $375K by -68.00%. The company's EBITDA was $-5.812M, missing the average prediction of $75K by -7849.44%. Viracta Therapeutics's net income was $-7.093M, missing the average estimation of $-96.542M by -92.65%. The company's SG&A was $2.23M, missing the average forecast of $3.93M by -43.27%. Lastly, the company's EPS was $-0.19, missing the average prediction of $-2.45 by -92.24%